The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression. The drug, SPRAVATO, is made by Johnson & Johnson and was first approved in 2019 for adults ...